Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang - LARVOL DELTA

Rebamipide for Managing Dyspeptic Symptoms During Proton-Pump Inhibitor Washout Before Helicobacter pylori Testing: A Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, Turk J Gastroenterol) - "The responder rate was higher in the rebamipide group, but the difference did not reach statistical significance. The poten tial benefit of rebamipide as a rescue therapy during the PPI washout period before H. pylori testing warrants further investigation in larger trials.   Cite this article as: Suksai N, Chueansuwan R, Yongsiri S, Witoon R, Juttuporn A. Rebamipide for managing dyspeptic symptoms during proton-pump inhibitor washout before Helicobacter pylori testing: A randomized, double-blind, placebo-controlled trial. Turk J Gastroenterol. 2026;37(2):251-259."

Clinical • Journal • Dyspepsia • Gastrointestinal Disorder • Infectious Disease • Pain

Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review. (PubMed, Pharmaceuticals (Basel)) - " Rebamipide demonstrates consistent therapeutic benefits across diverse gastrointestinal disorders, improving H. pylori eradication rates, mucosal protection, ulcer healing, and symptom relief. These findings support rebamipide as an effective and well-tolerated adjunctive agent for the prevention and management of upper gastrointestinal diseases."

Journal • Review • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

3D-Printed Implant Overdentures: Comparing Impression Techniques (clinicaltrials.gov) - P=N/A | N=16 | Recruiting | Sponsor: Mansoura University | Not yet recruiting ➔ Recruiting

Enrollment open

Pharmacist-Led Deprescribing Interventions for Older Adults with Polypharmacy: A Retrospective Cohort Study of Community Pharmacy Practice in Japan. (PubMed, Drugs Aging) - "Pharmacist-led deprescribing is infrequently implemented. Future studies could investigate the potential of strengthened incentives, enhanced collaboration, and robust protocols to optimize medication management in older adults."

Journal • Retrospective data

Expression and Roles of Free Radicals and Reactive Oxygen Species in Hearing Loss. (PubMed, Antioxidants (Basel)) - "Elevated ROS and free radicals appear to contribute to the pathogenesis of hearing loss. Although definitive conclusions cannot yet be drawn, current evidence suggests that antioxidant approaches may aid in prevention and treatment. Further studies are needed to elucidate underlying mechanisms, refine therapeutic targets and dosing, and validate efficacy in rigorously designed clinical trials."

Journal • Review • Cytomegalovirus Infection • Infectious Disease • Otorhinolaryngology • NOX4

Targeting the NLRP3-NEK7 axis with rebamipide: Drug repurposing in Parkinson's disease. (PubMed, Neural Regen Res) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • NLRP3

A Network Meta-Analysis of Pharmacological Treatments for Gastric Mucosal Protection in Artificial Ulcers Following Endoscopic Submucosal Dissection (ESD) of the Stomach. (PubMed, Pharmacology) - "PPI-based combinations likely accelerate healing versus PPI alone, but conclusions are hypothesis-generating given indirect evidence and regional concentration of trials. Combination therapy outperforms PPI monotherapy. BMG+PPI is optimal for early ulcer healing, EB+PPI for long-term healing, HT+PPI for diameter reduction, and TN+PPI for bleeding prevention. Stratified regimens by ulcer characteristics are recommended."

Journal • Retrospective data • Review

Investigation of the preventive action of rebamipide versus cadmium nephrotoxicity effect in rats. (PubMed, Ir J Med Sci) - "Rebamipide acts as a promising preventive agent against cadmium-induced nephrotoxicity, through its potent antioxidant and anti-inflammatory mechanisms."

Journal • Preclinical • Inflammation • Oncology • Renal Disease • BECN1 • CAT • KIM1 • MAP1LC3B • NFKB1 • TNFA

Inhibition of mycobacteria proliferation in macrophages by diaryl ether derivatives of Dehydrozingerone compound and repurposed drugs (Rebamipide, Sofalcone) via NF-κB pathway inhibition. (PubMed, Tuberculosis (Edinb)) - "Our results unequivocally validate NF-κB inhibition by DHZ (6), Sofalcone, and Rebamipide as a powerful strategy for HDT. These compounds are promising adjunct therapies to suppress host inflammation and limit tissue damage."

Journal • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • MMP2 • MMP9

Effects of rebamipide quadruple therapy with gastrointestinal endoscopy adjuvant therapy on gastrointestinal hormones in patients with gastric ulcer bleeding. (PubMed, Arab J Gastroenterol) - "Rebamipide therapy combined with gastrointestinal endoscopy is an effective treatment for gastric ulcer bleeding and demonstrates a high level of safety."

Journal • Peptic Ulcer • GAST

Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: October 6 University | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Sep 2025

Trial completion • Trial completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Rebamipide Induces Hair Regeneration Through EP4-Driven Lipid Metabolism Remodeling. (PubMed, Int J Mol Sci) - "Mechanistically, computer simulations and target validation experiments confirm that rebamipide directly binds to the prostaglandin E receptor EP4, triggering PI3K/ERK-dependent autophagy and lipolysis. Collectively, our findings highlight EP4 as a novel therapeutic target for hair loss and position rebamipide as an agent that couples lipid metabolism remodeling with HFSC activation."

Journal • Alopecia • Immunology • Metabolic Disorders • Peptic Ulcer

THE EFFICACY AND SAFETY OF HIGH-DOSE DUAL THERAPY FOR HELICOBACTER PYLORI ERADICATION IN THE NORTH-WESTERN REGION OF RUSSIA (UEGW 2025) - "pylori) infection is a common problem (prevalence of 32.7% in 2023) in the North-Western Federal District, comprising one-tenth of Russia, where primary resistance rates of clarithromycin and levofloxacin are >15%.1 The eradication rates remain low and do not reach the threshold value of 95% (eradication rate of 86.8% in 2023)...Patients were randomly allocated to two eradication groups: high-dose dual therapy for 14 days (esomeprazole 40 mg and amoxicillin 1000 mg three times daily) and optimized high-dose dual therapy for 14 days (esomeprazole 40 mg, amoxicillin 1000 mg, rebamipide 100 mg three times daily)... In the North-Western region of Russia, the fourteen-day optimized high-dose dual therapy with PPI-amoxicillin-rebamipide provided encouraging results (over 90% cure rates) and had the lower incidence rate of side effects (19.8%) suggesting as an alternative for H. pylori rescue treatment in the local region."

Clinical • Infectious Disease

EFFECTIVENESS OF REBAMIPIDE SUSTAINED-RELEASE TABLETS ON SUBJECTIVE SYMPTOMS IN PATIENTS WITH GASTRITIS: A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY [WITHDRAWN] (UEGW 2025) - No abstract available

Clinical • Observational data • Gastrointestinal Disorder

3D-Printed Implant Overdentures: Comparing Impression Techniques (clinicaltrials.gov) - P=N/A | N=16 | Not yet recruiting | Sponsor: Mansoura University

New trial

Comparative Efficacy and Safety of Stillen® and Rebamipide in Patients with Acute or Chronic Gastritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (PubMed, J Clin Med) - "Most studies were assessed as having a low risk of bias, and the certainty of evidence was rated as high for most efficacy outcomes. The network meta-analysis suggests that Stillen® is non-inferior to rebamipide in improving erosions in patients with acute or chronic gastritis."

Journal • Retrospective data • Review • Dyspepsia • Gastrointestinal Disorder • Pain

Repurposing of rebamipide as a neuroprotective agent to alleviate letrozole-induced depressive-like behaviors in female rats: Targeting SIRT1/FoxO1/wnt/ β-catenin, and related ferroptosis pathways. (PubMed, Life Sci) - "Reba has a major neuroprotective role via activating SIRT1 and inhibiting related oxidative, neuroinflammatory, and ferroptosis pathways."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Polycystic Ovary Syndrome • Psychiatry • CTNNB1 • GPX4 • NLRP3 • SIRT1 • SLC7A11 • TNFA

Rebamipide modulates the miR-29a/SIRT1/FoxO3a and NF-κB pathways in methotrexate-induced testicular damage. (PubMed, Eur J Pharmacol) - "Besides, REBA pretreatment potentiated the anticancer activity of METH in a mouse model of Ehrlich solid carcinoma (ESC) (histology with scoring). It was concluded that REBA protected against METH-induced testicular toxicity through modulating the miR-29a/SIRT1/FoxO3a, inflammation, and apoptosis pathways."

Journal • Oncology • Solid Tumor • CAT • FOXO3 • IL6 • MIR29A • TNFA

The high-dose dual therapy for eradication of Helicobacter pylori: efficacy and safety (PubMed, Ter Arkh) - "The efficacy of the Era-RebAmIPP regimen is comparable to conventional triple therapy with bismuth. To assess the effectiveness of this regimen, larger-scale studies are required in various regions of our country."

Clinical • Journal • Infectious Disease

Real-World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient-Focused Approach. (PubMed, Clin Transl Sci) - "The symptom improvement rate (≥ 50% reduction) was 71.5% in the monotherapy group and 71.4% in the combination therapy group, with no significant difference between the two groups (p = 0.976). Rebamipide monotherapy provided similar levels of GI symptom relief compared to combination therapy with PPIs in a real-world clinical setting."

Journal • Observational data • Real-world evidence • Gastrointestinal Disorder

Mosapride combined with rebamipide demonstrates superior efficacy for treatment of chronic atrophic gastritis. (PubMed, Am J Transl Res) - "The combination of mosapride and rebamipide offers superior efficacy in managing CAG without increasing adverse effects. It significantly improves pathological conditions, expedites symptom resolution, and enhances gastric mucosal biomarker profiles, supporting its broader clinical application."

Journal • Addiction (Opioid and Alcohol) • Gastrointestinal Disorder • EGF

Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: October 6 University | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Drug treatment strategies for erosive esophagitis in adults: a narrative review. (PubMed, Transl Gastroenterol Hepatol) - "Search terms encompassed various treatment modalities including PPIs, potassium-competitive acid blockers (P-CABs), histamine 2 receptor antagonists (H2RAs), sucralfate, prokinetics, rebamipide and alginates...Among PPIs, esomeprazole shows slightly better healing outcomes compared to others...The addition of nighttime to bedtime H2RAs or use of double PPI dose may benefit refractory cases. Further studies are needed to directly compare PPIs and P-CABs in different EE grades and evaluate the value of adjunctive therapies."

Journal • Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy for ESD induced gastric ulcers a randomized multicenter study. (PubMed, Sci Rep) - "The proportion of flat ulcer scar at week 8 was significantly higher in the combination group than in the tegoprazan monotherapy group (73.8% vs. 48.4%, P = 0.007). Combination treatment with rebamipide and tegoprazan led to faster ulcer healing and the development of high-quality post-ESD scars compared to tegoprazan monotherapy."

Clinical • Journal • Monotherapy • Gastric Cancer • Oncology • Peptic Ulcer

Comparative Efficacy of Treatments for Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer. (PubMed, Cureus) - "In contrast, rebamipide and benzydamine had higher complication rates (25% and 28%, respectively) and less significant symptom relief. Given its safety, efficacy, and minimal side effects, omega-3 nanoemulgel should be considered a first-line preventive treatment for oral mucositis in patients with head and neck cancer."

Journal • Review • Head and Neck Cancer • Mucositis • Oncology • Oral Cancer • Pain • Solid Tumor • Stomatitis